Form 4: Zimmer Biomet Director Robert Hagemann Reports Transactions

Robert Hagemann, a Director at Zimmer Biomet Holdings, Inc., has reported transactions related to phantom stock units under the company's Deferred Compensation Plan for Non-Employee Directors.

Summary

• Robert Hagemann, a Director of Zimmer Biomet Holdings, Inc. (ZBH), has filed a Form 4 detailing transactions involving phantom stock units.
• These phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The reported transaction date is June 30, 2026, with a conversion/exercise price of $86.65 per unit.
• A total of 317.369 phantom stock units were acquired.
• These units are to be settled in cash over five annual installments, starting within sixty days after the cessation of Hagemann's service as a Director.
• Following these transactions, Hagemann beneficially owns 33,269.443 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents routine compensation reporting for a director and does not contain new strategic information or financial performance data.

Positives

• The filing indicates continued participation and accrual of compensation for a director under a formal plan.
• The structure of the deferred compensation plan allows for phased cash settlement, potentially smoothing cash outflows for the company.
• The reporting person is a Director, suggesting ongoing engagement with the company's governance.

Negatives

• The filing does not contain any negative financial performance indicators or operational challenges.
• No specific financial metrics are presented in this transaction report.

Risks

• The value of the phantom stock units is tied to the company's stock performance, meaning any decline in ZBH's stock price would reduce the ultimate cash settlement value.
• The settlement of these units is contingent upon the reporting person's cessation of service as a Director, introducing a timing element to the cash payout.

Future Outlook

The future outlook related to this filing is primarily the eventual cash settlement of the phantom stock units, which will occur in five annual installments after the reporting person ceases to be a Director.

Industry Context

StockSavvy.ai notes that director compensation plans, including phantom stock units and deferred compensation, are common in the medical device industry to attract and retain experienced leadership. The structure reported for Zimmer Biomet is typical for non-employee directors.

Comparison to Industry Standards

• Many companies in the medical device sector, such as Medtronic and Abbott Laboratories, utilize similar deferred compensation plans and equity-based awards for their non-employee directors to align their interests with shareholders.
• The cash settlement in installments is a standard practice to manage cash flow and provide a long-term incentive.
• The reported exercise price of $86.65 for phantom stock units would be compared against the prevailing market price of ZBH common stock at the time of accrual and vesting.

Related Party Transactions

• The transaction involves phantom stock units accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors, which is a form of compensation to a related party (Director).

Stakeholder Impact

• Shareholders: The value of the phantom stock units is tied to the company's stock performance, indirectly aligning director interests with shareholder value. The cash settlement will impact company liquidity.
• Employees: No direct impact on employees is indicated by this filing.
• Creditors: The cash settlement of these units represents a minor claim on company assets.
• Management: Confirms the compensation structure for non-employee directors.

Next Steps

• Cash settlement of phantom stock units in five annual installments upon cessation of director service.
• Continued reporting of any further transactions by Robert Hagemann as required by SEC regulations.

Key Dates

Keywords

Zimmer Biomet, ZBH, Form 4, Director Compensation, Phantom Stock Units, Deferred Compensation Plan, Insider Transactions, Beneficial Ownership